Literature DB >> 18805453

Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.

Anna Koulova1, Jennifer Tsui, Kathleen Irwin, Pierre Van Damme, Robin Biellik, Maria Teresa Aguado.   

Abstract

We analysed country recommendations and funding plans finalized through January 2008 for the inclusion of quadrivalent and bivalent human papillomavirus (HPV) vaccines in national immunization programmes. Fifteen industrialized countries have recommended HPV vaccine use based on careful review of scientific evidence and cost-effectiveness. There was a strong consensus among the guidelines regarding assessment of vaccine safety and efficacy, selection of primary target populations for vaccination, vaccine delivery strategies, and the need for vaccinated females to seek cervical cancer screening. The analysis informs ongoing discussions in several countries considering HPV vaccines for national immunization programmes and discussions at the World Health Organization about global recommendations for HPV vaccine use for national immunization programmes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805453     DOI: 10.1016/j.vaccine.2008.08.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  Dr. Google: what about the human papillomavirus vaccine?

Authors:  Leticia Pías-Peleteiro; Javier Cortés-Bordoy; Federico Martinón-Torres
Journal:  Hum Vaccin Immunother       Date:  2013-06-06       Impact factor: 3.452

2.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

Authors:  Jessica A Kahn; Robert D Burk; Kathleen E Squires; Bill G Kapogiannis; Bret Rudy; Jiahong Xu; René Gonin; Nancy Liu; Carol Worrell; Craig M Wilson
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

3.  Acceptability of HPV vaccine among a national sample of gay and bisexual men.

Authors:  Paul L Reiter; Noel T Brewer; Annie-Laurie McRee; Paul Gilbert; Jennifer S Smith
Journal:  Sex Transm Dis       Date:  2010-03       Impact factor: 2.830

4.  Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women.

Authors:  Tasneem Shikary; David I Bernstein; Yan Jin; Gregory D Zimet; Susan L Rosenthal; Jessica A Kahn
Journal:  J Clin Virol       Date:  2009-08-08       Impact factor: 3.168

Review 5.  Monitoring of human papillomavirus vaccination.

Authors:  J Dillner; M Arbyn; E Unger; L Dillner
Journal:  Clin Exp Immunol       Date:  2010-11-09       Impact factor: 4.330

Review 6.  Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.

Authors:  Marjorie Jenkins; Maurizio Chiriva-Internati; Leonardo Mirandola; Catherine Tonroy; Sean S Tedjarati; Nicole Davis; Nicholas D'Cunha; Lukman Tijani; Fred Hardwick; Diane Nguyen; W Martin Kast; Everardo Cobos
Journal:  Int Rev Immunol       Date:  2012-02       Impact factor: 5.311

7.  Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Authors:  Dan Apter; Cosette M Wheeler; Jorma Paavonen; Xavier Castellsagué; Suzanne M Garland; S Rachel Skinner; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Henry C Kitchener; Julio C Teixeira; Unnop Jaisamrarn; Genara Limson; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Adrian Mindel; Philippe de Sutter; Karin Hardt; Toufik Zahaf; Dominique Descamps; Frank Struyf; Matti Lehtinen; Gary Dubin
Journal:  Clin Vaccine Immunol       Date:  2015-02-04

Review 8.  A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability.

Authors:  Jennifer D Allen; Gloria D Coronado; Rebecca S Williams; Beth Glenn; Cam Escoffery; Maria Fernandez; Raegan A Tuff; Katherine M Wilson; Patricia Dolan Mullen
Journal:  Vaccine       Date:  2010-04-20       Impact factor: 3.641

Review 9.  AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.

Authors:  Kate McKeage; Barbara Romanowski
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

Review 10.  Integrating clinical, community, and policy perspectives on human papillomavirus vaccination.

Authors:  María E Fernández; Jennifer D Allen; Ritesh Mistry; Jessica A Kahn
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.